ABO 1020
Alternative Names: ABO-1020Latest Information Update: 03 Feb 2023
At a glance
- Originator Suzhou Abogen Biosciences
- Class COVID-19 vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III COVID 2019 infections
Most Recent Events
- 23 Nov 2022 Phase-II/III clinical trials in COVID-2019 infections (Prevention, In volunteers) in United Arab Emirates (IM) (NCT05636319; ABO1020-301)